| IGF-1R inhibitors |
| dalotuzumab plus ridaforolimus plus exemestane | ganitumab plus endocrine therapy |
| la/mBC - HR positive 2 | | |
| la/mBC - HR positive - (neo)adjuvant (NA) 3 | | |
| la/mBC - HR positive - NA - PIK3CA mutant | | |
| la/mBC - HR-positive - 1st line (L1) 13 | | |
| la/mBC - HR positive - L1 - PIK3CA mutant 1 | | |
| la/mBC - HR-positive - 2nd line (L2) 20 | | |
| la/mBC - HR positive - L2 - all population 1 | | |
| la/mBC - HR positive - L2 - PIK3CA mutant 1 | | |